Astellas submits application for marketing approval of enzalutamide for prostate cancer

Astellas Pharma Inc. (TOKYO: 4503) and Medivation, Inc. (NASDAQ: MDVN) today announced that Astellas has submitted an application for marketing approval of enzalutamide (generic name) to the Ministry of Health, Labour and Welfare in Japan for the treatment of prostate cancer.

Enzalutamide is a novel, once-daily, oral androgen receptor signaling inhibitor. It inhibits multiple steps in the androgen receptor signaling pathway, which has been shown to decrease cancer cell growth and can induce cancer cell death (apoptosis).

This filing application is based mainly on results obtained from the global Phase 3 trial (the AFFIRM trial) and a Phase 1-2 trial conducted in Japan.


Astellas Pharma US, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Portable diagnostic device deployed in sub-Saharan Africa to identify cases of Kaposi sarcoma